Organovo Holdings ( (ONVO) ) just unveiled an update.

DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB US: DMGGF) (FRANKFURT: 6AX) ("DMG"), a leading vertically integrated ...

Revvity, Inc. , today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United ...

Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today ...

Organovo (ONVO) announces that its oral presentation of its lead clinical stage drug FXR314 by Dr. Eric Lawitz of the Texas Liver Institute and the University of Texas Health San Antonio was featured ...

Shares of ONVO stock opened at $0.38 on Tuesday. Organovo has a fifty-two week low of $0.32 and a fifty-two week high of $1.74. The firm has a market cap of $5.84 million, a P/E ratio of -0.36 and a ...

New NCCN Guidelines for Patients: Quitting Smoking showcases attainable and uplifting options that empower people with cancer ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Organovo Holdings Inc. (ONVO) on Friday reported a loss of $2.5 million in its fiscal second quarter. The San Diego-based company said it had a loss of 14 ...

Organovo Holdings Inc. ONVO) on Friday reported a loss of $2.5 million in its fiscal second quarter. The San Diego-based company said it had a loss of 14 cents per share.